Does avatrombopag (Sucoxin) cause blood clots and how to prevent it

Avatrombopag (Avatrombopag) is an oral thrombopoietic drug (TPO receptor agonist), mainly used to treat thrombocytopenia and aplastic anemia related to chronic liver disease. Because this drug increases platelet count by stimulating the bone marrow to produce platelets, it may increase the risk of thrombosis in some patients. Especially when platelets rise too quickly or to a high level, the risk of venous or arterial blood clots may increase.

The risk of thrombosis is closely related to the patient's underlying disease. For example, patients with past risk factors such as deep vein thrombosis, pulmonary embolism, cardiovascular disease, or obesity need to be more vigilant about thrombotic events when using avatrombopag. Therefore, in clinical practice, the patient's risk of thrombosis is usually assessed before starting medication and an individualized monitoring plan is developed.

In terms of preventing thrombosis, doctors generally recommend: first, strictly control the platelet target value to avoid platelets rising too fast or exceeding the safe range; second, patients should maintain moderate exercise and avoid long-term bed rest or sitting; in addition, high-risk patients may need to combine low-dose anticoagulation or antiplatelet drugs, but this must be done under the guidance of a doctor to balance platelet elevation and bleeding risk.

During the medication, patients should regularly monitor platelet count and necessary blood indicators. If platelets are found to rise too fast or thrombosis symptoms such as chest tightness, difficulty breathing, and limb swelling occur, they should seek medical attention immediately. Through reasonable dosage control, standardized monitoring and lifestyle intervention, most patients can effectively reduce the risk of thrombosis while ensuring therapeutic efficacy.

Reference materials:https://www.drugs.com/